Skip to Content
Søg Menu
8.-16. juni 2023

Følg med når vi dækker EHA 2023 l European Hematology Association’s Annual Congress

Nyheder fra EHA 2022

Tillæg af andengenerations-FLT3-inhibitor til intensiv kemoterapi og konsolidering hos voksne med AML

  • / Daniel Kristensen

Højdepunkter fra EHA webinar 2022

Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
Lymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

MEDtalks fra EHA 2022

AML

Treatment Options for FLT3 mutant acute myeloid leukemia

/ Hæmatologi / Eunice Wang

UK NCRI AML19 Trial – Liposomal daunorubicin and cytarabine had a significant survival benefit

/ Hæmatologi / Jad Othman

AML patients with FLT3-ITD and wild-type NPM1 has a significant improvement of LFS, OS and GRFS

/ Hæmatologi / Ali Bazarbachi

AML-highlights fra ASH22 – i dansk perspektiv

/ Hæmatologi / Hans Beier Ommen

Evidence to use MRD after induction therapy of AML

/ Hæmatologi / Jacqueline Cloos
Se oversigt

CLL

Updated results on AVO therapeutic triplet regimen in untreated patients with CLL

/ Onkologi / Christine Ryan

CLL – The impact of using ibrutinib as front-line treatment

/ Hæmatologi / Ryan Jacobs

CLL – Update fra ASH 2022

/ Hæmatologi / Carsten Utoft Niemann

Significant longer PFS among patients who received zanubrutinib vs ibrutinib

/ Hæmatologi / Jennifer R. Brown

Several interesting combinations of therapies with Calquence for patients with CLL

/ Hæmatologi / Matthew S. Davids
Se oversigt

Lymfom

Axicabtagene ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients

/ Hæmatologi / Roch Houot

R/R Large B-cell Lymphoma: Interesting results from ASH 2022 for treatment with Yescarta (axicabtagene ciloleucel)

/ Hæmatologi / Frederick L. Locke

R/R AML: The benefit of intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation

/ Hæmatologi / Johannes Schetelig

The impact of the molecular profile and treatment of older and fragile patients with relapsed/refractory FLT3-mutated AML

/ Hæmatologi / Marina Konopleva

Værdien af højdosisbehandling som tillæg til Rvd induktion og konsolidering ved myelomatose

/ Hæmatologi / Agoston Gyula Szabo
Se oversigt

Myelomatose

Venetoclax plus obinutuzumab er den mest omkostningseffektive behandling af CLL uden del17p/TP53-mutationer

/ Hæmatologi / Matilde Slot

New combination shows promising efficacy in patients with triple-class refractory R/R multiple myeloma

/ Hæmatologi / Paul G. Richardson

BCMA-targeted and CAR-T cells therapies for multiple myeloma give a very exciting future and new hope for the patients

/ Hæmatologi / Sagar Lonial

Genomic aberrations as prognostic factors for time-limited Venclyxto, Venetoclax-based combinations

/ Hæmatologi / Eugen Taucsh

Sekventering og vurdering af behandlingsforløb ved CLL

/ Hæmatologi / Carsten Utoft Niemann
Se oversigt

Abstracts fra EHA 2022

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

/ Hæmatologi / BestPractice Nordic

Superior safety profile for decitabine vs chemotherapy for older patient with AML

/ Hæmatologi / BestPractice Nordic

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

/ Hæmatologi / BestPractice Nordic

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

/ Hæmatologi / BestPractice Nordic

Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL 

/ Hæmatologi / BestPractice Nordic

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

  • / BestPractice Nordic

Se highlights EHA webinar 2022

Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
Lymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Mere fra EHA 2022

Paolo Strati

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

/ Paolo Strati
EHA22Lymfom Play the Video
Kirsten Grønbæk

Hvad har GDPR betydet for den nordiske forskningsscene? Vigtigste take-aways fra EHA med Kirsten Grønbæk

/ Kirsten Grønbæk
EHA22 Play the Video
Othman Al-sawaf

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

/ Othman Al-sawaf
EHA22CLL Play the Video

Mere fra EHA 2021

Daniel Kristensen

Nyt landsdækkende studie stiller spørgsmålstegn ved betydningen af dosisreduktion hos overvægtige AML-patienter

/ Daniel Kristensen
EHA22AML Play the Video
Jean-Marie Michot

Novel oral agent with promising result as second-line treatment option for patients with T-Cell Lymphoma

/ Jean-Marie Michot
EHA22Lymfom Play the Video
Paul Richardson

A new randomized study suggests an improved depth of response and PFS for patients relapsing on Lenalidomide

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Arnon Kater

The main clinical message from the Five-Year Analysis of Murano Study

/ Arnon P. Kater
EHA22CLL Play the Video
Paul Richardson

Longer PFS and higher ORR for frailty patients with R/R Multiple Myeloma treated with PVd than Vd

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Jakob Nordberg Nørgaard

A new study shows that PTCD and MRD are complementary and necessary for doing a whole assessment on patient-response for myeloma patients

/ Jakob Nordberg Nørgaard
EHA22Myelomatose Play the Video
Læs mere
Paul Richardson

Treatment with RVD + stem cell transplant achieved higher PFS vs RV alone In patients with newly diagnosed multiple myeloma

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Jean-Marie Michot

Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma

/ Jean-Marie Michot
EHA22Lymfom Play the Video

The New Treatment Landscape of Multiple Myeloma in the Perspective of New Front-line Therapies

/ Claudio Cerchione
EHA22Myelomatose Play the Video
Back to top